UPDATE: BMO Capital Downgrades Akcea Therapeutics, Inc. (AKCA) to Market Perform Aug 31, 2020 04:04PM
Akcea Therapeutics (AKCA) PT Trimmed to $39 at BMO Capital; Pfizer Deal Provides 'Immediate Value' Oct 7, 2019 12:25PM
Akcea Therapeutics, Inc. (AKCA) PT Lowered to $43 at BMO Capital Aug 7, 2019 07:53AM
Akcea Therapeutics, Inc. (AKCA) PT Raised to $47 at BMO Capital Nov 6, 2018 03:52AM
Akcea Therapeutics, Inc. (AKCA) PT Raised to $40 at BMO Capital Aug 7, 2018 07:56AM


May 4, 2018 01:12AM Akcea Therapeutics, Inc. (AKCA) PT Lowered to $38 at BMO Capital
Feb 27, 2018 01:45AM Akcea Therapeutics, Inc. (AKCA) PT Raised to $30 at BMO Capital; '4Q17: Ready for Volanesorsen Launch'
Dec 7, 2017 07:00AM Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
Dec 7, 2017 07:00AM Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
Aug 8, 2017 05:11AM BMO Capital Starts Akcea Therapeutics, Inc. (AKCA) at Outperform
Jul 19, 2017 04:19PM Akcea Therapeutics (AKCA) Closes IPO, Reports $50M Private Placement with Novartis Pharma (NVS)
Jul 19, 2017 04:15PM Akcea Therapeutics Announces Closing of Initial Public Offering
Jul 14, 2017 10:53AM Akcea Therapeutics (AKCA) IPO Opens Modesty Higher
Jul 14, 2017 05:36AM Akcea Therapeutics (AKCA) Prices 15.625M Share IPO at $8/Sh
Jul 13, 2017 08:25PM Akcea Therapeutics Announces Pricing of Initial Public Offering
Jun 20, 2017 07:03AM Akcea Therapeutics (AKCA) Launches Proposed IPO with Initial Offering Price of $12 to $14/Share (IONS)
Jun 20, 2017 07:00AM Akcea Therapeutics Launches Proposed Initial Public Offering